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ABSTRACT
Introduction The aim of the cervical ripening at home 
or in- hospital—prospective cohort study and process 
evaluation (CHOICE) study is to compare home versus 
in- hospital cervical ripening to determine whether home 
cervical ripening is safe (for the primary outcome of 
neonatal unit (NNU) admission), acceptable to women and 
cost- effective from the perspective of both women and the 
National Health Service (NHS).
Methods and analysis We will perform a prospective 
multicentre observational cohort study with an internal 
pilot phase. We will obtain data from electronic health 
records from at least 14 maternity units offering only in- 
hospital cervical ripening and 12 offering dinoprostone 
home cervical ripening. We will also conduct a cost- 
effectiveness analysis and a mixed methods study to 
evaluate processes and women/partner experiences. 
Our primary sample size is 8533 women with singleton 
pregnancies undergoing induction of labour (IOL) at 
39+0 weeks’ gestation or more. To achieve this and 
contextualise our findings, we will collect data relating 
to a cohort of approximately 41 000 women undergoing 
IOL after 37 weeks. We will use mixed effects logistic 
regression for the non- inferiority comparison of NNU 
admission and propensity score matched adjustment 
to control for treatment indication bias. The economic 
analysis will be undertaken from the perspective of the 
NHS and Personal Social Services (PSS) and the pregnant 
woman. It will include a within- study cost- effectiveness 
analysis and a lifetime cost–utility analysis to account for 
any long- term impacts of the cervical ripening strategies. 
Outcomes will be reported as incremental cost per NNU 
admission avoided and incremental cost per quality 
adjusted life year gained.
Research ethics approval and dissemination CHOICE 
has been funded and approved by the National Institute of 
Healthcare Research Health Technology and Assessment, 
and the results will be disseminated via publication in 
peer- reviewed journals.
Trial registration number ISRCTN32652461.
INTRODUCTION
Induction of labour (IOL) is the most 
common obstetric intervention offered to 
women when risks of continuing the preg-
nancy are thought to outweigh risks of birth. 
Increases in IOL rates over the past 10 years 
mean that now 29.6% of all pregnant women 
in the UK have their labour induced.1 IOL 
at term, when compared with expectant 
management of pregnancy, reduces caesarean 
birth, maternal hypertensive disease and 
complications,2 as well as being associated 
with a reduction in perinatal mortality.3 4 The 
demands on maternity services are increasing 
to accommodate increasing rates of IOL.5 
Although IOL (compared with expectant 
management) reduces overall hospital stay, 
it increases the time on labour and delivery 
wards,2 having a major impact on resources, 
staffing and negatively impacts on women’s 
experience of labour.6–8
Cervical ripening is a key component of IOL.9 
It may initiate labour, but is often followed 
by artificial rupture of membranes±intrave-
nous oxytocin infusion. National Institute for 
Strengths and limitations of this study
 ► This is a large study to evaluate the safety of at- 
home cervical ripening.
 ► We will set up a platform for data collection using 
electronic health records to enable future research 
into rare safety outcomes.
 ► The study includes assessment of women’s views 
and experiences using validated questionnaires as 
well as qualitative methods.
 ► Observational design of the study makes it vulnera-
ble to residual confounding.
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Health and Care Excellence (NICE) guidance10 recom-
mends pre- induction cervical ripening in all women 
having IOL unless there is a contraindication.
Traditionally, cervical ripening has been performed 
entirely in- hospital, to allow monitoring of maternal/
fetal well- being and early recognition of complications.11 
However, an increasing number of UK maternity units 
offers outpatient (home) cervical ripening. As the rate 
of IOL is increasing, home cervical ripening may provide 
opportunities to reduce the burden on the NHS, for 
example, by reducing hospital stay during IOL. However, 
the safety and acceptability of home cervical ripening have 
not been fully evaluated. NICE10 identified the need to 
assess the safety, efficacy and clinical and cost- effectiveness 
of outpatient and inpatient IOL in the UK setting, taking 
into account women’s views. A recent Cochrane review 
found insufficient evidence to draw conclusions on the 
efficacy, safety and cost- effectiveness of home IOL and 
indicated that large prospective cohort studies would be 
needed.12 Maternity service users have identified IOL as 
an important research topic,13 and women have reported 
specific negative experiences such as increased pain and 
anxiety and lack of support which may be alleviated by 
home cervical ripening.8 Potential NHS cost savings of 
home cervical ripening could be offset by increased costs 
of any additional morbidity resulting from home cervical 
ripening, costs to parents may be increased and accept-
ability of home cervical ripening is unknown. Health 
services need to balance the full resource impact of IOL 
with the need to provide safe and acceptable care.
In the cervical ripening at home or in- hospital—prospec-
tive cohort study and process evaluation (CHOICE) study, 
we will perform an observational cohort study with a cost- 
effectiveness analysis and process evaluation to address 
the question, ‘Is it safe, effective, cost- effective and accept-
able to women to carry out home cervical ripening during 
IOL?’. These analyses will provide information to help 
women and their caregivers make informed decisions 
around how to have IOL.
Our main aim is to compare the setting of cervical 
ripening at home versus in- hospital. As the NICE 
recommended agent for cervical ripening is vaginal 
prostaglandin, our primary comparison will be home 
dinoprostone versus in- hospital dinoprostone. In order to 
future- proof the study, we will include a secondary compar-
ison: home cervical ripening with balloon catheter versus 
home cervical ripening with dinoprostone. By including 
two different methods of home cervical ripening within 
our study, we will provide initial comparative evidence on 
these two methods of home labour induction.
METHODS AND ANALYSIS
CHOICE: a prospective cohort study
Study design and setting
We will carry out a prospective multicentre cohort study 
using de- identified clinical data from electronic hospital 
records. The primary outcome will be non- inferiority of a 
neonatal unit (NNU)/special care admission for 48 hours 
or longer, initiated within 48 hours of birth.
The study will be performed in at least 26 UK obstetric 
units, 14 of which offer exclusively in- hospital cervical 
ripening and 12 offer dinoprostone cervical ripening 
both in- hospital and at home.
Participating maternity units will be purposively 
selected to represent the diverse range of maternity 
service settings in the UK, and include urban tertiary 
referral units, mid- sized urban district general hospitals 
and small, more isolated, rural units.
Data sources
Data will be collected directly from electronic maternity 
(and neonatal) records for participants who had babies 
admitted to an NNU. These data are recorded by clin-
ical staff (midwives, doctors and neonatal nurses) during 
the course of antenatal, intrapartum and postpartum 
care. Existing data fields, supplemented by new bespoke, 
data entry fields enabled in the maternity dataset at 
participating sites will be used. Unless women opt out 
of secondary data use (from similar studies, we estimate 
<1% will opt out), de- identified data will be transferred 
from participating sites to a secure University of Edin-
burgh server for analysis.
No personal data will be collected. Potentially iden-
tifiable data, such as the date and time of birth, date 
of events such as commencing cervical ripening and 
hospital discharge, will be converted into gestation at 
birth (weeks+days); and antenatal and postnatal events 
into ‘t–x’ and ‘t+x’ hours and days, respectively.
Population, inclusion and exclusion criteria
We will initially apply broad inclusion criteria and collect 
data from all women having IOL at 37+0 weeks’ gestation 
or more to create a cohort for analyses. Women who have 
opted out of data provision will be excluded.
We will then apply more stringent inclusion and exclu-
sion criteria at the analysis stage for a suite of nested anal-
yses. In our primary analysis, we will create a cohort of 
women with ‘uncomplicated’ (ie, those with no identified 
risk factors for adverse maternal or perinatal outcomes 
defined below) pregnancies in whom there was no contra-
indication to home cervical ripening, who had singleton 
pregnancies with IOL at 39 weeks’ gestation or more. This 
group will include women having IOL for post- dates, but 
also women having IOL because of maternal or clinician 
preference, IOL for maternal age and IOL for discom-
fort or social indications. Exclusion criteria will consist of 
grand multiparity (six or more previous births), previous 
caesarean section, antepartum stillbirth (before cervical 
ripening initiated), class III obesity at booking (body 
mass index (BMI): 40 kg/m2 or more), prelabour rupture 
of membranes (ROM) documented as primary or other 
indication for IOL (prolonged ROM, spontaneous ROM 
and suspected spontaneous ROM), maternal or fetal 
condition that would or could preclude home cervical 
ripening documented as primary or other indication for 
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IOL (maternal conditions: proteinuria; hypertension; 
antepartum haemorrhage; diabetes; obstetric cholestasis; 
obstetric history; pre- eclampsia; pregnancy induced 
hypertension (PIH)/pre- eclampsia (PET) (not defined); 
PIH; PET; thrombophilia; fetal conditions: oligohy-
dramnios; reduced liquor volume; macrosomia; intra-
uterine growth restriction; static growth; congenital fetal 
anomaly; polyhydramnios; abnormal cardiotocograph 
(CTG)/Doppler; breech; reduced fetal movements and 
termination of pregnancy for fetal anomaly).
We will explore the potential for additional analyses, 
which may include IOL for other indications (eg, reduced 
fetal movements) or in other populations (eg, multiple 
pregnancies and women with a previous caesarean 
birth). However, in general, home cervical ripening is 
only offered to ‘low risk’ women, so we anticipate that 
numbers of higher risk women having home IOL may not 
be high enough for meaningful analyses.
Exposure and outcomes
Our primary aim is to compare home versus in- hospital 
cervical ripening. We will collect data at individual level. 
The exposure group will be women who, at the start of 
the cervical ripening process, plan to have home cervical 
ripening. The comparator group will be women who 
planned to have in- hospital cervical ripening from mater-
nity units not offering home cervical ripening. This will 
minimise potential bias arising from the fact that, in 
maternity units which offer both home and in- hospital 
cervical ripening, the risk of complications in the babies 
of women having home cervical ripening (lower risk 
pregnancies) is inherently different to that of babies of 
women having in- hospital cervical ripening (higher risk 
pregnancies).
As the NICE recommended agent for cervical ripening 
is vaginal prostaglandin, our primary comparison will 
be home dinoprostone versus in- hospital dinoprostone. 
Dinoprostone is now most commonly administered as 
10- mg slow- release pessary (Propess, Ferring), which stays 
in place for 24 hours. We will use this formulation in our 
primary comparison.
We will include a secondary exploratory comparison—
home cervical ripening with balloon catheter (expo-
sure) versus home cervical ripening with dinoprostone 
(comparator), to explore if there are any indications of 
different safety profiles of these two methods of home 
cervical ripening.
Our proposed primary outcome will be admission to an 
NNU/special care baby unit for 48 hours or longer, initi-
ated within 48 hours of birth. NNU admission is a marker 
of neonatal morbidity and is the leading core outcome 
defined for studies of IOL.14 Any increase in NNU admis-
sion of term babies is undesirable due to the separation 
of mother and baby. However, NNU admission rates are 
highly variable between maternity units and are likely to 
depend on local policies and culture. We, therefore, plan 
to use a primary outcome, which represents more severe 
neonatal morbidity (admission to a NNU within 48 hours 
of birth for 48 hours or longer), which is less likely to 
be influenced by site- specific factors. We may re- define 
the parameters of NNU admission used in the primary 
outcome after analysis of pilot data (see section ‘Pilot 
phase’).
We have prespecified a number of secondary outcomes 
to assess the safety of home cervical ripening with 
respect to neonatal and maternal morbidity, listed in 
table 1. These include outcomes from a core outcome 
set for studies of IOL.14 We will also include secondary 
outcomes relating to the effectiveness of home cervical 
ripening and to explore whether the setting of cervical 
ripening influences subsequent labour and birth. Mother 
and baby outcomes were suggested by our lay consulta-
tion as important to include. We will use birth weight, 
birth weight centile, small for gestational age and large 
for gestational age as parameters to check the validity of 
our matching procedures in analyses. Birth weight is an 
objective outcome that may represent pregnancy compli-
cations, but extremely unlikely to be affected by the 
setting of cervical ripening. Comparison of birth weights 
between groups should provide reassurance that we have 
minimised systemic bias in our analyses.
Statistical analysis
All analyses will be fully specified in a comprehensive 
Statistical Analysis Plan and agreed by the Steering 
Committee. Analyses will be carried out in accordance 
with relevant guidance, including Reporting of studies 
Conducted using Observational Routinely- collected Data 
(RECORD)15 and Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE).16
We will include at least 14 maternity units offering 
only in- hospital cervical ripening and 12 offering dino-
prostone home cervical ripening (~95 000 deliveries per 
annum). We will invite additional maternity units to opt 
in to data provision, to allow contingency in case of ‘cross 
overs’ due to sites changing their IOL protocols during 
the study period.
We considered a superiority design for CHOICE, but 
decided against it because (a) safety is a key concern 
to both clinicians and women, and was specified as the 
important outcome in the commissioning brief; (b) it is 
not plausible to hypothesise that home cervical ripening 
(intervention) is safer than in- hospital cervical ripening 
(comparator—the standard of care) and (c) it is not 
ethical to use a superiority design to test an intervention, 
which may be worse (in terms of safety) than the estab-
lished standard. Therefore, a non- inferiority design was 
chosen with a non- inferiority margin of 4% (deemed as 
likely to be an important difference on consultation with 
women and clinicians) for the primary outcome of NNU 
admission.
Establishing the appropriate non- inferiority margin 
was complicated by recognition that the dimensions that 
are hypothesised to show benefit, that is, acceptability to 
women and partners, and a reduction in costs appeal to 
different audiences—women will be primarily interested 
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Table 1 Secondary outcomes
Safety outcomes Baby
Any neonatal unit (NNU) admission (any level of care)
Neonatal intensive care unit (NICU) admission
Duration of NNU stay
Duration of NICU stay
Apgarscore <7 at 5 min
Apgar score <4 at 5 min
Arterial cord blood pH <7.1
Arterial cord base excess >12 mmol/L
Neonatal seizures
Hypoxic ischaemic encephalopathy (as recorded by care 
givers)
Level 2 or level 3 hypoxic ischaemic encephalopathy (as 




Stillbirth after admission/first attendance for induction of 
labour (excluding deaths from congenital anomalies)
Early neonatal death up to 7 days after birth (day 0–6; 
excluding deaths from congenital anomalies)
Treatment for neonatal sepsis (defined as positive blood, 
cerebral spinal fluid, or urine culture or cardiovascular 
collapse or X- ray confirming infection) (exploratory outcome)
Treatment in NNU for neonatal infection (defined as 
antibiotic treatment and temperature ≥37.5°C or <35.5°C) 
(exploratory outcome)
Treatment for neonatal jaundice (defined as peak total 
bilirubin of at least 15 mg or the use of phototherapy) 
(exploratory outcome)
Maternal
Intensive care unit transfer
High dependency level care
Hyperstimulation or tachysystole (as 
defined by care givers)
Hyperstimulation or tachysystole 
causing cardiotocograph (CTG) 
abnormality (as defined by care givers)
Umbilical cord prolapse
Birth outwith hospital
Postpartum haemorrhage 1000 mL or 
more
Maternal fever 38°C or more after 
commencing cervical ripening 
(exploratory outcome)
Effectiveness outcomes Time from first cervical ripening agent to admission to labour ward/birth unit
Time from first cervical ripening agent to birth
More than one cervical ripening agent used
Duration of antenatal hospital stay for cervical ripening
Duration of labour ward admission until birth
Duration postnatal hospital stay (mother)
Total hospital stay
Hours spent at home
Oxytocin use
Mode of birth
Birth in obstetric unit
Birth in alongside midwifery unit (if available at that site)
Mother baby outcomes Breastfeeding at discharge from maternity care
Skin to skin at birth
Cost effectiveness Primary health economic outcomes
Incremental cost per neonatal admissions avoided (home vs in- hospital)
Incremental quality adjusted life year (QALYs) (home vs in- hospital)
Other (exploratory) economic outcomes
Incremental cost per hour prevented from hospital admission to delivery/birth
Incremental cost per neonatal admission avoided (home balloon catheter vs home dinoprostone)
Incremental cost per QALY (home balloon catheter vs home dinoprostone)
Incremental cost per hour prevented from hospital admission to delivery/birth (home balloon catheter 
vs home dinoprostone)





Small for gestational age (<10th centile for gestational age)
Large for gestational age (>90th centile for gestational age)
Continued
 on M
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in acceptability and largely indifferent to costs (in a free 
at point of care NHS), whereas the potential reduction 
in costs will likely be the primary focus for the healthcare 
provider. We were also conscious that due to the inflation 
of the sample size due to (a) clustering, (b) losses due 
to non- matching in the propensity analysis and (c) loss 
to follow- up, the sample size for a smaller non- inferiority 
margin would quickly become not feasible within a real-
istic budget and timeframe. Given that, regardless of a 
superiority or non- inferiority design, any specific sample 
size will estimate the treatment effect to a certain level of 
precision (eg, the width of a 95% CI), we are confident 
that our final comparison group of 1920 in each arm (with 
~115 NNU admissions in each arm (see sample size calcu-
lation below)), we will generate sufficient high- quality 
evidence to definitively answer the questions around 
safety, effectiveness, acceptability and cost- effectiveness 
for this important question
For the principal analysis of the primary outcome, we 
will use mixed effects logistic regression for the non- 
inferiority comparison of NNU admission within 48 hours 
of birth for 48 hours or longer (Yes/No). As sensitivity 
analyses to demonstrate that the estimated treatment 
effects are robust to the chosen method, we will also 
explore propensity score weighting (by inverse probability 
of receiving specified treatment) and single- stage regres-
sion, without using any propensity scoring, adjusting 
directly for the baseline factors relevant for treatment 
indication. We will also use propensity score matched 
(PSM) adjustment to control for treatment indication 
bias. The logistic model underlying the PSM will include 
variables such as age, Bishop’s score, previous vaginal 
birth, c- morbidities and relevant hospital- level factors, 
with 1:1 matching. Potential confounding variables will 
be identified before the start of the analysis, and these will 
be finalised after exploration of the data at the pilot stage, 
through the creation of directed acyclical graphs.
Similar analyses will be used for analyses of secondary 
outcomes, using logistic, linear, negative binomial and 
time- to- event regressions. For example, we will analyse 
the duration of hospital stay during IOL, time spent at 
home, total hospital stay and time to birth using linear 
models; while birth outwith hospital and breastfeeding 
will be analysed using logistic regression; and mode of 
birth using multinomial logistic regression.
For the remaining maternal secondary outcomes, 
we will include hyperstimulation, ≥1 induction agent, 
oxytocin use for induction or augmentation, maternal 
ICU/High dependency unit admission, haemorrhage, 
uterine rupture, pulmonary embolus and cardiorespi-
ratory arrest. For the neonatal secondary outcomes, we 
will include meconium aspiration syndrome, respiratory 
support, neonatal infection, umbilical cord prolapse, 
neonatal birth trauma, neonatal encephalopathy (Grade 
II/III), therapeutic hypothermia and neonatal death. 
Logistic regression and Poisson or negative binomial 
regression, possibly inflated for excess zeros will be used as 
appropriate. For outcomes with a small number of events, 
we will use the appropriate exact regression procedure. 
As per the primary outcome, we will assess the influence 
of missing data for secondary outcomes using appro-
priate sensitivity- type analyses. We recognise that there 
are many secondary outcomes being analysed, as per the 
recommended core outcome set.17 We do not propose to 
make any formal statistical adjustment for the multiple 
comparisons. However, a caveat will be clearly expressed 
regarding the possibility of type 1 statistical error, given 
the multiple comparisons made. We will consider the 
following subgroup analyses, based on sufficient numbers 
to allow meaningful analyses: (a) nulliparous and parous 
women; (b) indication for IOL (post- dates IOL; maternal 
or clinician preference; maternal age and discomfort or 
social indication).
We propose the following sensitivity analyses: (a) 
within- site comparison of home versus in- hospital 
cervical ripening (restricted to sites that offer home 
cervical ripening), (b) per protocol analysis (women 
who actually are discharged home after commencing 
cervical ripening) and (c) complete case analysis to 
assess the effect of any strategies to deal with missing 
data.
Data from the larger cohort of women having IOL at 
37+0 weeks’ gestation or more will be used to contextu-
alise our findings on the background of unit practices 
and populations undergoing IOL. There is consider-
able inter- unit variation in both the rates of IOL and 
the risk profile of women giving birth, that needs to be 
considered. It will also allow us to capture any changes in 
practice over the study period regarding criteria for eligi-
bility for home cervical ripening and change in method 
of IOL. This will help ensure the generalisability of our 
findings.
Future long- term outcome evaluation will be possible 






Sense of control (agentry) in labour
Secondary qualitative outcomes
Women’s satisfaction with induction of labour care
Women’s postnatal psychological well- being
Women’s overall evaluation of their labour and birth experience (qualitative analysis)
Costs incurred by the woman and family
Table 1 Continued
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Missing data
We anticipate missing data, but estimate that no more 
than 10% of women will have missing usable data on 
primary outcome, eligibility, setting of cervical ripening 
and/or have some part of the baseline data (age, comor-
bidities and any relevant identified hospital- level factors). 
We will use evidence- based strategies to minimise any such 
losses and recover any missing data that is possible. We 
will monitor levels of missing data as the study progresses, 
identifying any outcomes or exposures and/or sites that 
are prone to missingness, and take corrective action 
(eg, additional feedback and support). We will conduct 
appropriate sensitivity type analyses, for example, using a 
multiple imputation approach assuming data are missing 
at random, and if the data warrant (eg, if there is differ-
ential missingness between the in- hospital and at- home 
cohorts) non- ignorable (informative) missing data gener-
ating mechanisms.
We will also conduct an exploratory analysis comparing 
the two methods of home IOL, that is, dinoprostone versus 
mechanical methods. We will use the same methods as 
outlined above for the primary and secondary outcomes 
in the overall analysis.
Sample size
The sample size is based on our principal analysis (women 
with singleton pregnancies having IOL at 39 weeks’ gesta-
tion or more) and primary comparison (home cervical 
ripening vs in- hospital cervical ripening with dinopro-
stone), estimated 6% NNU admission rate1 for babies 
born to mothers having IOL at >39 weeks’ gestation with 
no more than 4% excess NNU admission rate (from 
6%), at 90% power, 2.5% one- sided alpha and an esti-
mated ICC of 0.01. We will require 160 women in each 
of 12 sites (clusters) with uncomplicated pregnancies at 
39 weeks or more undergoing IOL (total 1920 in each 
arm). To account for the fact that (a) only around 50% 
of women eligible for home cervical ripening in the inter-
vention arm will actually initiate home cervical ripening, 
and (b) a larger pool of women is required in the control 
arm to allow for propensity score matching, our required 
sample size is 1920×2 (number of arms)/0.5 (numbers 
of women actually starting home cervical ripening and 
matching)/0.9 (for missing data), giving an overall 
required sample size of 8533.
Based on an estimate that 22% of all maternities have 
IOL at 39 weeks or more1 and that ~29% of these would 
be eligible for participation in our principal analysis 
(from scoping data from potential participating sites), 
and, in home cervical ripening sites ~50% of these will 
take up home cervical ripening, we anticipate achieving 
our recruitment targets within 20 months.
Current data from the National Maternity and Perinatal 
Audit (NMPA) for 2019 suggests that the national average 
rate of IOL after 37 weeks is 29.6%.1 As our proposed 
participating units have about 90 000 births per annum, 
we anticipate collecting data on approximately 41 000 
women having IOL at 37 weeks’ gestation or more.
Participant identification and opt out
Participants will be identified from data recorded in spec-
ified fields in electronic maternity records. We will use 
data fields indicating IOL, estimated due date and date of 
IOL to identify women having IOL at 37 weeks’ gestation 
or more.
Women will be made aware of the CHOICE study 
through posters in participating sites; business cards; 
information leaflets; online adverts on hospital/mater-
nity websites and relevant social media sites; and informa-
tion in maternal electronic maternity records.
Women will be able to opt out of data provision by noti-
fying their clinician or midwife, or emailing the study 
research midwife at the local site, and it will be recorded 
on their electronic record. There will be no restriction on 
co- enrolment in other studies.
Pilot phase
We propose a pilot phase to determine the parameters 
of the primary outcome and feasibility of obtaining the 
required sample size for analysis. This is based on the 
evaluable comparison group of 1920 women in each arm, 
so acts as an inherent check on home cervical ripening 
eligibility and uptake rates, the assumed level of missing-
ness and attrition due to non- matching. We will assess 
variation of the primary outcome at the pilot stage, 
along with that of other measures of neonatal morbidity 
included as secondary outcomes (eg, any NNU admis-
sion and neonatal intensive care unit admission). We may 
redefine the parameters of NNU admission used in the 
primary outcome after analysis of pilot data, choosing the 
one with the lowest ICC or the one representing the least 
severe outcome, which has an ICC of 0.01 or less. This 
decision will be made in consultation between the expert 
project management group, the trial steering committee 
and the funder.
CHOICE health economic analyses
Health economic analysis will be specified in a health 
economic analysis plan and reported in line with Consol-
idated Health Economic Evaluation Reporting Standards 
guidelines.18
Economic analyses will explore the cost effectiveness 
of at home versus inpatient cervical ripening for women 
undergoing IOL. Two separate cost- effectiveness ques-
tions will be addressed: (a) home cervical ripening with 
dinoprostone compared with in- hospital cervical ripening 
with dinoprostone and (b) home cervical ripening with 
balloon catheter compared with home cervical ripening 
with dinoprostone. The evaluation will involve within 
study cost- effectiveness analysis and a lifetime cost–
utility analysis to account for any long- term impacts 
(cost and morbidity) of the alternative cervical ripening 
strategies. Resource use data will be obtained from the 
prospective multicentre observational cohort study using 
data obtained from the maternity information system, 
Badgernet Maternity and National Neonatal Research 
Database (NNRD) data.
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Costs incurred by women and their families relating 
to IOL are relevant from the patient perspective and 
potentially important for the ‘at- home’ cervical ripening 
strategy. These data are not available from the observa-
tional datasets, and, therefore, tailored economic- related 
questions have been incorporated into a process evalua-
tion survey described in section five below.
To account for bias in the observational data, methods 
such as multivariate regression and propensity scoring 
will be employed as recommended in guidelines for cost- 
effectiveness analysis based on observational data,19 20 
which is consistent with the main study statistical analyses 
for this study. To capture any cost and morbidity events 
incurred in the neonatal period, the within- study analysis 
will include the primary study endpoint (NNU admis-
sion within 48 hours of birth for 48 hours or more) up 
to 1- month after birth. Outcomes will be reported as the 
incremental cost per NNU admission avoided (in line 
with primary study outcome) as well as incremental cost 
per birth up to 28 days after birth.
The lifetime analysis will account for longer term costs, 
quality of life, morbidity and disability from both the NHS 
and PSS and patient perspective and will report outcomes 
in terms of incremental cost per quality adjusted life years 
gained.
Qualitative (q)CHOICE process evaluation
The process evaluation, nested within the observational 
cohort study, will comprise of a questionnaire- based 
survey in at least 12 sites and 5 case studies. Both qualita-
tive and quantitative data will be collected, specifically a 
women’s experience questionnaire, semi- structured inter-
views with women and birth partners, audio recordings 
of clinician/women consultations, interviews and focus- 
group discussions with professionals. Figure 1 describes 
the initial process evaluation logic model hypothesising 
the chain linking interventions and outcomes. This will 
inform data collection and analysis. At the final stage of 
data analysis, we will share and discuss emerging findings 
with a group of service users to develop a revised logic 
model and explanatory framework.
Questionnaire-based survey
Questionnaire data collection will take place over a 4–6- 
month period early in the study. CHOICE participating 
sites who use electronic maternity records accessible by 
women (the electronic equivalent of maternity hand- 
held records) will be invited to contribute to this part 
of the study. Women who have IOL at 39 weeks or more 
will receive a ‘push or SMS notification’ directing them 
to online study information when IOL is booked and a 
second notification around 10 days after they give birth. 
Figure 1 Logic model for the qCHOICE process evaluation. ARM, artificial rupture of membranes; CR, cervical ripening; IOL, 
induction of labour; NHS, National Health Service; OPIOL, Home cervical ripening; qCHOICE, qualitative cervical ripening at 
home or in- hospital—prospective cohort study and process evaluation.
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This will provide a link to the participant information 
sheets, consent form and online survey.
Push notifications are used by maternity services to 
prompt women to read information relating to their 
maternity care, including information within their elec-
tronic record. Women are able to opt out of SMS and 
push notifications, but routine monitoring of women’s 
use of their online record shows that a sufficient number 
of women use notifications and continue to access their 
record postnatally, thus enabling a broad sample to be 
reached.
The survey landing page will include a summary of 
qCHOICE and links to the information sheets before 
directing women to the consent questions, which they are 
asked to complete before completing the survey. A tele-
phone number will be supplied for women to call if they 
have any questions about the survey, or to request a postal 
survey if preferred. Surveys will be submitted online via 
online surveys,21 by post or completed by phone with a 
member of the study team, with the support of an inter-
preter if needed. Participant contact details provided 
by survey respondents who are happy to be contacted 
further about a possible interview will be on a detach-
able back sheet of the questionnaire or a separate online 
page. Respondents will be informed that a £10 voucher 
will be offered to interview participants and that (with 
their consent) their birth partners may take part in an 
interview.
The survey will comprise validated tools as well as ques-
tions relating to service user costs, and the process of IOL 
as follows:
1. The Labour Agentry Scale (LAS; short form)22: the 
LAS is a well- established, validated measure of wom-
en’s experience during labour and birth. The short- 
form LAS includes 10 items with a 7- point Likert- type 
response. It measures perceived control during labour, 
which is the woman’s sense of mastery over internal 
and environmental factors and is highly correlated 
with satisfaction with care. The LAS will be the primary 
outcome.
2. A modified version of the IOL satisfaction question-
naire23 tested in the Balloon Catheter Versus Propess 
for Labour Induction (PROBIT- F) trial.24 This ques-
tionnaire focuses specifically on women’s experiences 
of aspects of IOL, including information, anxiety and 
physical and emotional discomfort.
3. The short- form Warwick- Edinburgh Mental Well- Being 
Scale (WEMWBS)25: a seven- item scale that measures 
mental well- being (as opposed to mental illness or dis-
order) representing positive attributes of well- being, 
including feeling and functioning.
4. Additional questions, which will inform the econom-
ic analysis from the woman’s perspective, will cover 
resource use and expenditures of cervical ripening 
for women, including number of returns and phone 
calls to hospital, time distance, mode of travel to and 
from hospital, partner role, additional expenditure 
on maternity items and medication while at home, 
and additional childcare expenditure (if any) while 
at home.
5. The survey will include demographic questions, ques-
tions about the process of IOL, questions relating to 
the impact of COVID-19 19 on their experience of 
IOL, a question asking women if they would be willing 
to be contacted regarding possible participation in a 
semi- structured interview and for permission for data 
linkage to the observational cohort study.
Survey data will be analysed using descriptive and infer-
ential statistics. Descriptive statistics with 95% CIs will be 
reported for the total sample (by planned mode of cervical 
ripening—home or hospital, by actual mode (as some women 
who plan one mode may in practice have a different mode) 
and by study site). We will examine whether there are statisti-
cally significant differences in the primary outcome of sense 
of control (labour agentry) and by psychosocial outcome 
of postnatal psychological well- being score (WEMWBS) 
between women with home cervical ripening and women 
with in- hospital ripening. The covariates will include the 
reason for IOL, gestational age, maternal age, parity, sociode-
mographic status and ethnic group.
The sample size required to compare the experiences 
of women who had home and hospital cervical ripening is 
estimated to be 46 subjects within each of 12 sites (assuming 
equal numbers within each site), that is, 552 women in 
total. This is based on use of LAS26 where a change of 5.5 
points is considered clinically meaningful. In an individually 
randomised study, to have 90% power at a 5% level of signif-
icance to detect an effect size of 0.5 (two- sided), we would 
need 85 evaluable subjects per arm (170 total). However, 
this has to be inflated for the clustering within each site. 
We assume that the intraclass correlation coefficient is 0.05 
in this setting. We will also inflate the target sample by 10% 
to account for incomplete data/unusable questionnaires, 
aiming for 613 women in total.
We will invite all sites using accessible electronic maternity 
records to participate in the survey, but with the option to 
opt out. We will include at least 12 sites, that is, a total of at 
least 43 200 births annually across the sites. Our previous 
experience of questionnaire- based surveys, and the UK’s 
national maternity experience suggest a response rate of 
40%. With an estimated eligibility of 22% of all maternities 
having IOL at 39 weeks or more, and 15% of these having 
home cervical ripening. We expect to achieve our sample 
size within 4 months and will monitor recruitment rates from 
each site and, if necessary, extend the survey period to ensure 
an adequate sample.
Case studies
In- depth case studies will be undertaken at five sites. The 
sample of five case studies is pragmatic, and selection is 
designed to balance depth with breadth of information and 
analysis with sites chosen to provide diversity and balance of 
service types on the basis of geography, service configura-
tion and approaches to provision of IOL. We will undertake 
semi- structured interviews with women, their partners and a 
range of staff and stakeholders in each site. A topic guide and 
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pathway mapping will be used to help focus the discussion. 
Interviews will explore perceptions and experiences of the 
service approach to induction and implementation of local 
cervical ripening protocols in practice.
Women and partner interviews
Women will be eligible for interview if they have IOL at a 
gestation of 39+0 weeks gestation or more, have given birth in 
one of the case study sites and responded to the survey indi-
cating a willingness to be contacted regarding the interview.
A purposive sample of women will be included. A sampling 
frame will be constructed within and across case study sites 
with the aim of including a balance of nulliparous and 
parous women, women who were offered outpatient cervical 
ripening but declined, women who experienced this and 
women who were not offered it. The women approached 
will be given the opportunity to ask further questions and at 
least 1 week to decide whether to participate in an interview. 
Interviews will be conducted online or by telephone using a 
verbal consent protocol prior to the start of the interview. All 
women who consent to participate in an interview will also be 
asked whether they give consent for their birth partner to be 
invited for an interview. We anticipate interviewing between 
10 and 15 women in each site (total 50–75 participants) 
and, assuming that around half of participants may have a 
birth partner willing to participate, we anticipate including 
around 25–38 birth partners. If couples express a preference 
to be interviewed together, this will be accommodated. ‘Birth 
partner’ will be defined by the women themselves.
Key professionals, stakeholders and maternity professionals’ 
interviews and focus groups
Key professionals and stakeholders for interviews will be 
identified with the support of the Principal Investigator for 
each local case study service but will typically include: head 
of midwifery, clinical director, consultant obstetricians and 
midwives, chairs of local Maternity Voices Partnerships, 
representatives from local maternity service user groups and 
service commissioners or health board leads. Interviews will 
be conducted online or by telephone. Verbal consent will be 
obtained at the start of the interview. We anticipate under-
taking around 10 individual interviews in each case study site.
Midwives and obstetricians will be invited to participate 
in focus group discussions and we estimate that three focus 
groups comprising of 6–8 participants (total 18–24 partici-
pants) will be held in each site. These will be organised to 
facilitate participation of a diversity of maternity profes-
sionals, by including in a local audit meeting or study day. 
Focus groups may be held online or in person if access to the 
case study site is possible.
Observations of maternity visits discussing IOL
A small convenience sample of maternity visits will be included 
in each case study site in order to enable analysis of infor-
mation provision and women’s information needs. Up to 
five maternity professionals in each site will be provided with 
a digital recorder and given instructions on use and asked 
to record three consecutive interviews with the woman’s 
consent. We will follow- up the recorded consultations with 
a brief (up to 10 min) telephone interview to explore the 
woman’s understanding of the information provided.
Qualitative data analysis
All qualitative data will be transcribed and entered into the 
analysis support software NVivo to support data manage-
ment and analysis. Documentary sources will be added to 
the NVivo project file as PDF files. Visual approaches will be 
used to support the discussion and analysis of the pathways. 
Recordings of discussions will be analysed using a structured 
approach to conversation analysis. Interviews with women, 
partners and health professionals will be transcribed and 
analysed using a thematic framework approach, based on 
frameworks developed in the recent work by the study team 
as part of the PROBIT- F trial.8 27
RESEARCH ETHICS APPROVAL AND DISSEMINATION
CHOICE has National Research Ethics Service Committee 
approval (York and Humber—Sheffield Research Ethics 
Committee, REC reference: 20/YH/0145), National R&D 
approval in Scotland (NHS Research Scotland Permissions) 
and England (Health Research Authority), and approval 
from the Public Benefit and Privacy Panel in Scotland is 
pending. The study will be conducted in accordance with the 
principles of the International Conference on Harmonisa-
tion Tripartite Guideline for Good Clinical Practice.
Results will be submitted for peer- reviewed academic 
publication and presented at international conferences. 
Meta- data produced in this study will also become available 
to Health Data Research UK Gateway. STROBE guidance16 
and RECORD guidance15 will be used to guide transparent 
reporting.
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